Semaglutide (Wegovy, Ozempic) : Once-weekly injection Works on GLP-1 receptors 10-15% average body weight loss in clinical trials FDA-approved for chronic weight management Well-studied and proven effective Tirzepatide (Mounjaro, Zepbound) : Weekly injection Works on both GLP-1 and GIP receptors (dual action) Newer but showing strong results Can be effective for people who havent responded to semaglutide Risk is minimized when prescribed and monitored by a medical professional, such as a nurse practitioner or physician
Cagrilintide as a standalone medication is earlier in development, so an individual approval is likely further out, possibly 2028 or beyond
Limitations The number of studies enrolled was limited, and their quality was not high
See you on the next video
Support your bodys master antioxidantglutathionewith this powerful blend designed to help enhance liver detoxification, reduce oxidative stress, strengthen the gut lining, boost immunity, and protect against free radicals